

VIEWPOINT

Beyond Serendipity to an Algorithmic Approach

Shaghayegh Harbi, MS, PhD*; Ali Soltani, MD†; Hannah Lui Park, MS, PhD‡

emangiomas are heterogeneous vascular tumors (comprising endothelial cells, pericytes, myeloid cells, fibroblasts, and mast cells), have a unique natural history, and eventually involute into fibrofatty residuum (adipogenesis), which replaces the vascular tissue.¹⁻³ Most hemangiomas become apparent postnatally (do not proliferate in utero), reflective of the "maturation of the immune system in development (a layered immune system with distinct lineages [multilineage fetal and adult system] and homeostatic regulation of subsets [innate and adaptive immune traits] differentially influenced by genetic and environmental factors)".1 In the field of tumor immunology and immunotherapy, hemangiomas of infancy can serve as a remarkable tumor model to better the understanding and range of immune responses and the mechanisms that regulate inflammatory and antitumor responses for diagnostic, prognostic, and therapeutic applications, and more specifically to serve as a model for the development of an algorithmic approach to inform on (1) clinical management, treatment strategy and (2) design, development of definitive therapies.

Currently, clinical management is limited to observation. Surgical and nonsurgical treatment modalities have mixed results (as well as potential adverse effects and/or rebound growth [incidence of rebound growth was 25.3% for aggressive tumors²]) with therapeutic strategies of drugs commonly used in the management of hemangiomas based on inhibition of angiogenesis (steroid therapy, interferons [IFNs], vincristine, bleomycin, propranolol, cyclophosphamide, and thalidomide⁴). We propose that the development of definitive therapies requires a robust understanding of the maturation of the host immune system in development, innate and adaptive immune systems with respect to (1) the manifestation of tumorigenesis and the environmental factors that influence immune maturation; (2) the actual mechanisms involved in potential teratogenic immunomodulation and tumorigenesis; and (3) the modulation of an inflammatory response.⁵ Environmental factors influence immune maturation and the impact of *in utero* exposures on homeostatic regulation of

From the *VasculoTox, Inc., New York, N.Y.; †Department of Plastic Surgery, Kaiser Permanente, Irvine, Calif.; and ‡Department of Epidemiology, University of California Irvine, School of Medicine, Irvine, Calif.

Copyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Plast Reconstr Surg Glob Open 2018;6:e1675; doi:10.1097/ GOX.000000000001675; Published online 6 February 2018. immune system maturation can vary and inform on *early life exposures and potential susceptibility to disease.*

ALGORITHMIC APPROACH

We hypothesize that the vascular tumor growth curve corresponds to immune system development and the homeostatic regulation of immune system maturation, with tumor cessation corresponding to immune cell functionality and the transitions in fetal and adult immune cells (graceful transitions and an orchestrated switch; Fig. 1). Understanding the specific crosstalk between the host immune system and tumorigenesis during the stages of tumor development is important, for example, to identify the strategies tumors use to evade immunosurveillance and the therapeutic application of immunotherapy *beyond serendipity to an algorithmic approach.*

> *Shaghayegh Harbi, MS, PhD* VasculoTox, Inc. New York, N.Y. E-mail: shaghayegh.harbi@vasculotox.com

DISCLOSURE

ClinicoPathological Correlation (CPC) Single-Cell Assays, Immune Signatures Panels, and Technologies for Monitoring Immune System can be developed to evaluate the impact of in utero exposures on homeostatic regulation of immune system maturation. Illumina Grant for proof-of-concept (holder). NIH SBIR Grant (applicant). Patent (applicant). The Article Processing Charge was paid for by the authors.

REFERENCES

- Harbi S, Park H, Gregory M, et al. Arrested development: infantile hemangioma and the stem cell teratogenic hypothesis. *Lymphat Res Biol.* 2017;15:153–165.
- Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. *Pediatrics*. 2016;4:137.
- Soltani AM, Reinisch JF. Algorithmic approach to the management of hemangiomas. J Craniofac Surg. 2011;22:585–588.
- Mabeta P, Pepper MS. Hemangiomas—current therapeutic strategies. Int J Dev Biol. 2011;55:431–437.
- Vilcek J. From IFN to TNF: a journey into realms of lore. Nat Immunol. 2009;10:555–557.




Fig. 1. Tumor growth curve, immune system development (*wishbone curve*), and ontogeny of immune response. A, Tumor growth curves (reprinted with permission from Dr. Mulliken). B, Immune system in prenatal and postnatal development—curve reflecting normal, graceful transitions in fetal and adult immune cells, and an orchestrated switch (eg, developmental switch of T helper cell [TH2] to [TH1] immunity). C, Immune system maturation and adult immune cell functionality curve. ClinicoPathological Correlation (CPC) Single-Cell Assays, Immune Signatures Panels, and Technologies for Monitoring Immune System can be developed to evaluate the impact of *in utero* exposures on homeostatic regulation of immune system maturation. Reprinted with permission from Harbi et al.¹, 2017.